GlobalRPh Cardiovascular Risk and Advanced Lipid Analyzer

Enter any available lipid, lipoprotein, metabolic, kidney, and clinical risk data. The tool interprets each available value, calculates derived lipid measures and ratios, generates a detailed final lipid/apolipoprotein narrative, and calculates AHA PREVENT risk only when all required inputs are present.

Version 1.9 - Updated for the 2026 ACC/AHA dyslipidemia guideline

Which labs should a patient discuss with their physician?

Not every person needs every test. The goal is to start with the standard lipid panel, add high-yield inherited or particle-risk markers, and then select metabolic or kidney tests according to age, history, medications, and clinical risk.

Start with a standard lipid panel

Request total cholesterol, LDL-C, HDL-C, and triglycerides. Together they provide the basic lipid pattern and allow calculation of non-HDL-C and several supportive ratios.

  • LDL-C remains a primary treatment target.
  • HDL-C and triglycerides help identify broader metabolic and remnant patterns.
  • A fasting sample is not always required, but may be useful when triglycerides are high or a prior result was difficult to interpret.

High-yield additions

Lp(a): Discuss a one-time adult measurement because it is inherited, is not included in a standard lipid panel, and can identify risk that would otherwise remain hidden.

ApoB: Consider when triglycerides are elevated, diabetes or obesity is present, LDL-C is already low on therapy, or LDL-C may not fully reflect the number of atherogenic particles.

Metabolic and kidney context

Depending on the clinical situation, useful tests may include hemoglobin A1c or fasting glucose, serum creatinine with eGFR, and urine albumin-creatinine ratio.

  • A1c or fasting glucose helps identify diabetes or prediabetes-range glycemia.
  • eGFR and uACR help identify kidney-related cardiovascular risk.
  • Blood pressure, smoking status, diabetes history, and medication use are also needed for PREVENT risk calculation.

Selective tests, not routine for everyone

hsCRP may add context when inflammation-related risk remains uncertain. ApoA-I and ApoB:ApoA-I ratio are supplementary. Coronary artery calcium is an imaging test, not a blood test, and is most useful when a treatment decision remains uncertain after the initial risk review.

Practical tip: Bring the actual laboratory report with units and reference ranges. Medication use, fasting status, pregnancy, recent illness, and prior untreated values can materially change interpretation.

Patient and cardiovascular risk inputs

No field is required for the laboratory review. A complete PREVENT estimate requires age 30-79, sex, total cholesterol, HDL-C, systolic blood pressure, BMI, eGFR, and the four yes/no clinical fields.

Basic informationStandard lipidsAdditional lipid testsBody size and BMIMetabolic and kidneyPREVENT fields

Basic information

years
Guide: accepted 18-100; PREVENT is validated for ages 30-79; 30-year estimates for ages 30-59.
Use: required for PREVENT and sex-specific HDL-C, ApoA-I, and ratio interpretation.

Standard lipid panel

mg/dL
Guide: <200 desirable; 200-239 borderline high; >=240 high.
mg/dL; optional if the other lipid values permit Sampson-NIH estimation.
Guide: <100 descriptive desirable; 100-159 above desirable; >=160 high; >=190 severe. Risk goals may be <100, <70, or <55.
mg/dL
Guide: low if <40 male or <50 female; >=60 is higher. HDL-C is not a treatment target.
mg/dL
Guide: <150 normal; 150-499 elevated; >=500 severe; >=1,000 requires prompt review.

Advanced lipid and biomarker testing

mg/dL
Guide: <90 desirable; 90-129 above desirable; >=130 risk-enhancing. Lower goals may apply with higher risk.
mg/dL
Guide: common adult laboratory reference: >=120 male; >=140 female. Use the reporting laboratory range.
Guide: nmol/L: <75 low; 75-124 intermediate; >=125 high; >=250 very high.
Use: select the laboratory-reported unit. Do not use a fixed conversion factor.
mg/L
Guide: <2 below risk-enhancer threshold; 2-9.9 risk-enhancing if persistent; >=10 repeat when stable.
Agatston units
Guide: 0 none detected; 1-99 mild; 100-299 moderate; >=300 high. Age and sex percentile also matter.

Body size and BMI calculator

Choose one measurement system, then enter height and weight. BMI updates automatically. Age and sex are entered once in Basic information and are not part of the adult BMI formula.

Height and weight
BMI calculates automatically and is used by PREVENT when complete.
Height
ft
in
lb
Standard: enter height in feet and inches and weight in pounds.
BMI preview: Enter height and weight.
BMI already known? Enter it instead
kg/m2
Adult guide: <18.5 underweight; 18.5-24.9 healthy range; 25-29.9 overweight; >=30 obesity. When both methods are available, the height-and-weight calculation is used and compared with the entered BMI.

Metabolic, blood pressure, and kidney inputs

mm Hg
Guide: <120 normal; 120-129 elevated; 130-139 stage 1; >=140 stage 2.
mL/min/1.73 m2
Guide: >=90 G1; 60-89 G2; 45-59 G3a; 30-44 G3b; 15-29 G4; <15 G5. CKD requires persistence or kidney damage.
mg/g
Guide: <30 A1; 30-299 A2; >=300 A3. Confirmation is usually needed.
%
Guide: <5.7 normal; 5.7-6.4 prediabetes; >=6.5 diabetes range if confirmed.
mg/dL
Guide: 70-99 normal; 100-125 impaired fasting glucose; >=126 diabetes range if confirmed.

Required yes/no fields for PREVENT

Use: required for PREVENT; leave blank only when unknown.
Use: required for PREVENT; leave blank only when unknown.
Use: required for PREVENT; leave blank only when unknown.
Use: required for PREVENT; leave blank only when unknown.

Clinical context and risk enhancers

Check a box only when the condition is known to be present. An unchecked box means not reported in this tool, not necessarily confirmed absent.

General reference ranges and thresholds

MeasureGreenYellowRed or high-priority threshold
Total cholesterol<200 mg/dL200-239 mg/dL>=240 mg/dL
LDL-C<100 mg/dL general descriptive range100-159 mg/dL>=160 mg/dL; >=190 mg/dL is severe hypercholesterolemia
HDL-C>=60 mg/dL40-59 men; 50-59 women<40 men; <50 women
Triglycerides<150 mg/dL150-499 mg/dL>=500 mg/dL; >=1,000 requires prompt review
Non-HDL-C<130 mg/dL general range130-159 mg/dL>=160 mg/dL
ApoB<90 mg/dL90-129 mg/dL>=130 mg/dL risk-enhancing level
ApoA-ICommon adult reference: >=120 male; >=140 femaleLaboratory-specific borderline zoneBelow the reporting laboratory reference range
ApoB:ApoA-I ratioLower-risk: <0.70 male; <0.60 femaleAverage-risk: 0.70-0.90 male; 0.60-0.80 femaleHigher-risk: >0.90 male; >0.80 female
Lp(a), nmol/L<7575-124>=125; >=250 is very high
Lp(a), mg/dL<3030-49>=50; >=100 is very high
hsCRP<2 mg/L2 to <10 mg/L if persistent>=10 mg/L: repeat when clinically stable
Adult BMI18.5-24.9 kg/m2 healthy-weight range<18.5 underweight or 25-29.9 overweight>=30 obesity range; interpret as a screening category
A1c<5.7%5.7-6.4%>=6.5%
Fasting glucose<100 mg/dL100-125 mg/dL>=126 mg/dL
eGFR>=6030-59<30 mL/min/1.73 m2
uACR<30 mg/g30-299 mg/g>=300 mg/g

These are general interpretive bands, not universal treatment goals. Laboratory methods, biologic variation, fasting status, age, sex, pregnancy, comorbidities, medications, and overall risk can change interpretation.

Methodology and references

PREVENT model details

The application implements the published AHA PREVENT base equations for 10-year total CVD, ASCVD, and heart failure in adults aged 30-79 without known CVD. Thirty-year estimates are displayed only for ages 30-59. Inputs include age, sex, total cholesterol, HDL-C, systolic blood pressure, antihypertensive treatment, smoking, diabetes, statin use, BMI, and eGFR.

LDL-C estimation

When LDL-C is not entered and total cholesterol, HDL-C, and triglycerides are available, the application uses the Sampson-NIH equation. Estimated LDL-C is not produced when triglycerides exceed 800 mg/dL. Direct or laboratory-calculated LDL-C should be used when available and clinically appropriate.

Expanded narrative, missing-data review, and graphs

Version 1.9 retains the rule-based clinical narrative, missing-data review, semicircular SVG gauges, educational explanations, and color-coded input categories. It redesigns the BMI entry area with a single Standard or Metric selector, grouped height fields, one weight field with a changing unit label, automatic unit conversion, and a clearly separated direct-BMI fallback.

  1. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation. Published 2026.
  2. Khan SS, Matsushita K, Sang Y, et al. Development and Validation of the American Heart Association PREVENT Equations. Circulation. 2024;149:430-449.
  3. Bajaj A, Ballantyne CM, Boffa MB, et al. Focused Update to the 2019 National Lipid Association Scientific Statement on Use of Lipoprotein(a) in Clinical Practice. Journal of Clinical Lipidology. 2024.
  4. Sampson M, Ling C, Sun Q, et al. A New Equation for Calculation of LDL Cholesterol. JAMA Cardiology. 2020;5:540-548.
  5. American Diabetes Association. Standards of Care in Diabetes - 2026; ADA diagnostic thresholds for A1c and fasting plasma glucose.
  6. National Kidney Foundation. GFR categories G1-G5 and albuminuria categories A1-A3.
  7. 2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.
  8. Soffer DE, Marston NA, Maki KC, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an expert clinical consensus from the National Lipid Association. Journal of Clinical Lipidology. 2024.
  9. Mayo Clinic Laboratories. Apolipoprotein B/A1 Ratio, Serum: adult ApoA-I and ApoB:ApoA-I interpretive bands. Accessed 2026.
  10. Cleveland Clinic. Non-HDL Cholesterol: What It Is and Normal Range. Updated January 9, 2026.
  11. National Lipid Association. The importance of non-HDL cholesterol reporting in lipid management and patient-centered dyslipidemia recommendations.